fda vertex pharmaceuticals

Vertex Pharmaceuticals Stock Jumps

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 8h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

The Associated Press on MSN · 6h

FDA Approves First New Non-Opiod Painkiller in Decades

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

3hon MSN

Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

AFP11h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Vertex Pharmaceuticals Stock Jumps

Trending now